Bristol-Myers Squibb – Update to recall of Eliquis® (apixaban)

- On June 17, 2017, the FDA announced that the recall of one lot of Bristol-Myers Squibb's Eliquis (apixaban) 5 mg tablets has been de-escalated from a consumer-level to a **retail/dispensing-level** recall.
    - Patients should not stop taking Eliquis without consulting with their physician.
- The recall was initiated due to a customer complaint that a bottle labeled as Eliquis 5 mg was found to contain Eliquis 2.5 mg tablets.
- The recalled lot was distributed in February 2017.

Product Description	NDC #	Lot # (Expiration date)
Eliquis (apixaban) 5 mg tablets, 60-count bottle	0003-0894-21	HN0063 (9/2019)

- Eliquis is indicated for the following: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery; treatment of DVT and PE; and to reduce the risk of recurrent DVT and PE following initial therapy.
- Bristol-Myers Squibb has notified wholesalers and pharmacies to arrange for return and replacement of any recalled product. Consumers that have any recalled product should contact their healthcare provider and contact Bristol-Myers Squibb at **1-800-332-2056** for return and reimbursement information.
- Consumers should contact their healthcare provider if they have experienced any problems that may be related to taking Eliquis.